Drug Details
| General Information of the Drug (ID: DR4000) | ||||
|---|---|---|---|---|
| Name |
Marbofloxacin
|
|||
| Synonyms |
Marbofloxacin; 115550-35-1; Zeniquin; Marbocyl; UNII-8X09WU898T; 8X09WU898T; MFCD00864820; 7H-Pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,3,4]oxadiazino[6,5,4-ij]quinoline-6-carboxylic acid; NCGC00166310-01; DSSTox_CID_26600; DSSTox_RID_81755; DSSTox_GSID_46600; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,3,4]oxadiazino[6,5,4-ij]quinoline-6-carboxylic acid; Marbofloxacine [INN-French]; Marbofloxacinum [INN-Latin]; 9-Fluoro-3,7-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2H-[1,3,4]oxadiazino[6,5,4-ij]quinoline-6-carboxylic Acid; Marbofloxacino [INN-Spanish]; CAS-115550-35-1; Marbofloxacin [INN:BAN]; Marbofloxacine/; CCRIS 8212; 9-Fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid; PubChem16145; Marbofloxacin (USP/INN); Oprea1_079403; 9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(3,2,1-ij)(4,1,2)benzoxadiazine-6-carboxylic acid; cc-422; SCHEMBL134860; CHEMBL478120; DTXSID4046600; CHEBI:94723; EX-A015; ZINC537947; HY-B0126; RKL10084; Tox21_112406; ABP000382; ANW-42471; s1464; AKOS015853291; Tox21_112406_1; BCP9000896; CCG-229989; CS-1892; DB11426; GS-3323; NCGC00166310-02; NCGC00166310-03; 7H-Pyrido(3,2,1-ij)(4,1,2)benzoxadiazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-; 9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-piperazino)-7-oxo-7H-pyrido[1,2,3-ij][1,2,4]benzoxadiazine-6-carboxylic acid; AC-24289; AK327608; AB0105713; DB-041275; FT-0628168; M2240; D08156; AB01566820_01; 550M351; Marbofloxacin, VETRANAL(TM), analytical standard; Q909359; SR-01000772975; Q-201338; SR-01000772975-2; Marbofloxacin, European Pharmacopoeia (EP) Reference Standard; Marbofloxacin for peak identification, European Pharmacopoeia (EP) Reference Standard; 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2- diazatricyclo[7.3.1.0^5,13^]trideca-5,7,9(13),11-tetraene-11-carboxylic acid; 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2-diazatricyclo[7.3.1.0^{5,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid; 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2-diazatricyclo[7.3.1.0^{5,13}]trideca-5,7,9(13),11-tetraene-11-carboxylic acid; 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl -1-piperazinyl)-7-oxo-7H-pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid; 9-fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)- 7-oxo-7H-pyrido[1,2,3-ij][1,2,4]benzoxadiazine-6-carboxylic acid
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Chronic obstructive pulmonary disease [ICD-11: CA22] | Investigative | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C17H19FN4O4
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CN1CCN(CC1)C2=C(C=C3C4=C2OCN(N4C=C(C3=O)C(=O)O)C)F
|
|||
| InChI |
1S/C17H19FN4O4/c1-19-3-5-21(6-4-19)14-12(18)7-10-13-16(14)26-9-20(2)22(13)8-11(15(10)23)17(24)25/h7-8H,3-6,9H2,1-2H3,(H,24,25)
|
|||
| InChIKey |
BPFYOAJNDMUVBL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 115550-35-1
|
|||
| ChEBI ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Methyl gallate | Givotia rottleriformis | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vivo Model | Salmonella Typhimurium in rats were used in this study. | |||||
| Experimental
Result(s) |
MG has shown to increase the antimicrobial activity of MAR in vitro and ex vivo experiments without affecting the pharmacokinetics of MAR in rats. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | ERK activator kinase 1 (MEK1) | Molecule Info | [3] | |
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | ErbB signaling pathway | |||
| 3 | Ras signaling pathway | |||
| 4 | Rap1 signaling pathway | |||
| 5 | cGMP-PKG signaling pathway | |||
| 6 | cAMP signaling pathway | |||
| 7 | Chemokine signaling pathway | |||
| 8 | HIF-1 signaling pathway | |||
| 9 | FoxO signaling pathway | |||
| 10 | Sphingolipid signaling pathway | |||
| 11 | Oocyte meiosis | |||
| 12 | PI3K-Akt signaling pathway | |||
| 13 | Vascular smooth muscle contraction | |||
| 14 | Dorso-ventral axis formation | |||
| 15 | VEGF signaling pathway | |||
| 16 | Osteoclast differentiation | |||
| 17 | Focal adhesion | |||
| 18 | Gap junction | |||
| 19 | Signaling pathways regulating pluripotency of stem cells | |||
| 20 | Toll-like receptor signaling pathway | |||
| 21 | Natural killer cell mediated cytotoxicity | |||
| 22 | T cell receptor signaling pathway | |||
| 23 | B cell receptor signaling pathway | |||
| 24 | Fc epsilon RI signaling pathway | |||
| 25 | Fc gamma R-mediated phagocytosis | |||
| 26 | TNF signaling pathway | |||
| 27 | Long-term potentiation | |||
| 28 | Neurotrophin signaling pathway | |||
| 29 | Cholinergic synapse | |||
| 30 | Serotonergic synapse | |||
| 31 | Long-term depression | |||
| 32 | Regulation of actin cytoskeleton | |||
| 33 | Insulin signaling pathway | |||
| 34 | GnRH signaling pathway | |||
| 35 | Progesterone-mediated oocyte maturation | |||
| 36 | Estrogen signaling pathway | |||
| 37 | Melanogenesis | |||
| 38 | Prolactin signaling pathway | |||
| 39 | Thyroid hormone signaling pathway | |||
| 40 | Oxytocin signaling pathway | |||
| 41 | Prion diseases | |||
| 42 | Alcoholism | |||
| 43 | Hepatitis B | |||
| 44 | Influenza A | |||
| 45 | Pathways in cancer | |||
| 46 | Proteoglycans in cancer | |||
| 47 | MicroRNAs in cancer | |||
| 48 | Colorectal cancer | |||
| 49 | Renal cell carcinoma | |||
| 50 | Pancreatic cancer | |||
| 51 | Endometrial cancer | |||
| 52 | Glioma | |||
| 53 | Prostate cancer | |||
| 54 | Thyroid cancer | |||
| 55 | Melanoma | |||
| 56 | Bladder cancer | |||
| 57 | Chronic myeloid leukemia | |||
| 58 | Acute myeloid leukemia | |||
| 59 | Non-small cell lung cancer | |||
| 60 | Central carbon metabolism in cancer | |||
| 61 | Choline metabolism in cancer | |||
| NetPath Pathway | FSH Signaling Pathway | Click to Show/Hide | ||
| 2 | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Angiogenesis | Click to Show/Hide | ||
| 2 | B cell activation | |||
| 3 | EGF receptor signaling pathway | |||
| 4 | Endothelin signaling pathway | |||
| 5 | FGF signaling pathway | |||
| 6 | Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade | |||
| 7 | Integrin signalling pathway | |||
| 8 | PDGF signaling pathway | |||
| 9 | T cell activation | |||
| 10 | Toll receptor signaling pathway | |||
| 11 | VEGF signaling pathway | |||
| 12 | Ras Pathway | |||
| 13 | Angiotensin II-stimulated signaling through G proteins and beta-arrestin | |||
| 14 | CCKR signaling map ST | |||
| Pathwhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | Click to Show/Hide | ||
| 2 | Insulin Signalling | |||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | Click to Show/Hide | ||
| 2 | Endothelins | |||
| 3 | BCR signaling pathway | |||
| 4 | GMCSF-mediated signaling events | |||
| 5 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
| 6 | EPHB forward signaling | |||
| 7 | SHP2 signaling | |||
| 8 | Netrin-mediated signaling events | |||
| 9 | mTOR signaling pathway | |||
| 10 | Class IB PI3K non-lipid kinase events | |||
| 11 | IL2-mediated signaling events | |||
| 12 | Ras signaling in the CD4+ TCR pathway | |||
| 13 | Ceramide signaling pathway | |||
| 14 | IFN-gamma pathway | |||
| 15 | ErbB1 downstream signaling | |||
| 16 | ErbB2/ErbB3 signaling events | |||
| 17 | FOXM1 transcription factor network | |||
| 18 | PDGFR-beta signaling pathway | |||
| 19 | Neurotrophic factor-mediated Trk receptor signaling | |||
| 20 | Nongenotropic Androgen signaling | |||
| 21 | Hedgehog signaling events mediated by Gli proteins | |||
| 22 | CXCR3-mediated signaling events | |||
| 23 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
| 24 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
| 25 | Cellular roles of Anthrax toxin | |||
| 26 | Trk receptor signaling mediated by the MAPK pathway | |||
| 27 | Downstream signaling in naï | |||
| 28 | ||||
| 29 | Signaling events mediated by focal adhesion kinase | |||
| Reactome | MAPK3 (ERK1) activation | Click to Show/Hide | ||
| 2 | Uptake and function of anthrax toxins | |||
| 3 | RAF activation | |||
| 4 | MAP2K and MAPK activation | |||
| 5 | Negative feedback regulation of MAPK pathway | |||
| 6 | MAP3K8 (TPL2)-dependent MAPK1/3 activation | |||
| WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
| 2 | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
| 3 | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||
| 4 | Serotonin HTR1 Group and FOS Pathway | |||
| 5 | Estrogen signaling pathway | |||
| 6 | TCR Signaling Pathway | |||
| 7 | ErbB Signaling Pathway | |||
| 8 | Hypothetical Network for Drug Addiction | |||
| 9 | Senescence and Autophagy in Cancer | |||
| 10 | EPO Receptor Signaling | |||
| 11 | Regulation of Actin Cytoskeleton | |||
| 12 | IL-2 Signaling Pathway | |||
| 13 | Insulin Signaling | |||
| 14 | EGF/EGFR Signaling Pathway | |||
| 15 | MAPK Cascade | |||
| 16 | MAPK Signaling Pathway | |||
| 17 | TGF beta Signaling Pathway | |||
| 18 | IL-6 signaling pathway | |||
| 19 | Signaling of Hepatocyte Growth Factor Receptor | |||
| 20 | Focal Adhesion | |||
| 21 | Kit receptor signaling pathway | |||
| 22 | IL-3 Signaling Pathway | |||
| 23 | Bladder Cancer | |||
| 24 | Cardiac Hypertrophic Response | |||
| 25 | MAP kinase activation in TLR cascade | |||
| 26 | RAF/MAP kinase cascade | |||
| 27 | Nanoparticle-mediated activation of receptor signaling | |||
| 28 | Structural Pathway of Interleukin 1 (IL-1) | |||
| 29 | Genes and (Common) Pathways Underlying Drug Addiction | |||
| 30 | Nifedipine Activity | |||
| 31 | Aryl Hydrocarbon Receptor | |||
| 32 | PDGF Pathway | |||
| 33 | BDNF signaling pathway | |||
| 34 | Integrated Pancreatic Cancer Pathway | |||
| 35 | Oncostatin M Signaling Pathway | |||
| 36 | Corticotropin-releasing hormone | |||
| 37 | Interleukin-11 Signaling Pathway | |||
| 38 | AGE/RAGE pathway | |||
| 39 | B Cell Receptor Signaling Pathway | |||
| 40 | Prostate Cancer | |||
| 41 | Signaling Pathways in Glioblastoma | |||
| 42 | TSLP Signaling Pathway | |||
| 43 | IL-9 Signaling Pathway | |||
| 44 | Endothelin Pathways | |||
| 45 | IL-7 Signaling Pathway | |||
| 46 | Leptin signaling pathway | |||
| 47 | TSH signaling pathway | |||
| 48 | RANKL/RANK Signaling Pathway | |||
| 49 | IL-1 signaling pathway | |||
| 50 | Signaling by FGFR | |||
| 51 | Integrin-mediated Cell Adhesion | |||
| 52 | L1CAM interactions | |||
| 53 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 54 | Regulation of toll-like receptor signaling pathway | |||
| 55 | Osteopontin Signaling | |||
| 56 | IL-5 Signaling Pathway | |||